Back to Journals » OncoTargets and Therapy » Volume 10

Ezh2, a novel target in detection and therapy of breast cancer

Authors Pourakbar S, Pluard TJ, Accurso AD, Farassati F

Received 4 April 2017

Accepted for publication 4 April 2017

Published 22 May 2017 Volume 2017:10 Pages 2685—2687

DOI https://doi.org/10.2147/OTT.S138777

Checked for plagiarism Yes

Sarah Pourakbar,1,2 Timothy J Pluard,3 Anthony D Accurso,1 Faris Farassati1,3

1Midwest Biomedical Research Foundation, Kansas City Veterans Affairs Medical Center, 2University of Missouri–Kansas City School of Medicine, 3Saint Luke’s Cancer Institute, Kansas City, MO, USA
 
In 2013, 232,340 new cases of invasive breast cancer and 39,620 breast cancer deaths were estimated among US women.1 Currently, one in eight women in the US will develop breast cancer in her lifetime, and breast cancer is the second leading cause of cancer death among women.1 Despite many therapeutic advances over the last 20 years, metastatic disease remains a major cause of death for breast cancer patients, elucidating a crucial problem in the overall management of patients.2 The 5-year survival rate for metastatic breast cancer is currently estimated as ,25%.3,4 


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

The role of KPNβ1 in neuro-oncology

Lilley M, Farassati F

OncoTargets and Therapy 2017, 10:2067-2068

Published Date: 10 April 2017

Editorial announcing PubMed indexing of Oncolytic Virotherapy

Farassati F

Oncolytic Virotherapy 2017, 6:19-20

Published Date: 15 February 2017